• Michael Charlton.
• Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. charlton.michael@mayo.edu
• Curr Opin Organ Transplant. 2013 Jun 1;18(3):251-8.

Purpose Of ReviewNonalcoholic steatohepatitis (NASH), obesity, and the metabolic syndrome are highly prevalent. NASH, a rare indication for liver transplantation in the early 1990s, is now the third most common indication. This review considers key aspects of the liver transplantation for NASH.Recent FindingsNASH is one consequence of obesity, almost always occurring in the context of metabolic syndrome and oxidative stress. Recurrence of NASH can be severe. The components of metabolic syndrome are often exacerbated following liver transplantation by factors such as immunosuppression, and are important predictors of patient morbidity and mortality. Many aspects of the metabolic syndrome are modifiable. The roles bariatric surgery, nutritional and pharmacotherapy of NASH, and the impact of established and new immunosuppressive agents have recently evolved.SummaryA nuanced approach is needed in management of obesity, metabolic syndrome, and immunosuppression in liver transplant recipients.

11 keywords...

hide…